Table.
Cases with Miller Fisher Syndrome and Guillain-Barré Syndrome after mRNA COVID-19 Vaccination without Infection and Other Vaccination.
| Diagnosis | Country | Age (years)/ Sex |
Vaccine type | Number of dose | Days from inoculation to onset | Neurological symptoms | CSF cells (/μL)/ Protein (mg/dL) |
Anti-ganglioside antibody | NC study | Treatment | Outcome | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MFS | Japan | 30/M | BNT162b2 | Second | 7 | Bilateral lateral gaze palsy, areflexia, and ataxic gait | 1/30.8 | GQ1b GT1a | Normal | IVIg | Recovered | Present case |
| GBS | Qatar | 73/M | BNT162b2 | Second | 16 | Muscle weakness, areflexia | Normal/80 | N.D. | Absent H reflexes | IVIg | Recovered | 2 |
| GBS | US | 82/F | BNT162b2 | First | 14 | Muscle weakness, sensory loss, areflexia | 4/88 | N.D. | N.D. | IVIg | Improved | 1 |
| GBS | US | 86/F | BNT162b2 | First | 1 | Muscle weakness, areflexia | 2/162 | N.D. | N.D. | IVIg | Recovered | 3 |
| GBS | US | 65/M | BNT162b2 | First | 2 | Bilateral facial palsy, muscle weakness, sensory loss, areflexia | 1/107 | N.D. | AIDP | IVIg | Improved | 5 |
| GBS | Mexico | 31/M | BNT162b2 | First | 11 | Muscle weakness, areflexia | Not performed | N.D. | AIDP | IVIg | Improved | 4 |
| GBS | Mexico | 67/F | BNT162b2 | First | 4 | Muscle weakness, areflexia, respiratory failure | 22/30 | N.D. | AMAN | IVIg | Dead | 4 |
MFS: Miller Fisher syndrome, GBS: Guillain-Barré syndrome, N.D.: not detected, AIDP: acute inflammatory demyelinating polyneuropathy, AMAN: acute motor axonal neuropathy, CSF: cerebrospinal fluid